Business Context and Reporting Period
This Form 8-K, filed on October 20, 2022, by Ra Medical Systems, Inc. (RMED), reports on a joint press release with Catheter Precision, Inc. The filing details the expansion of Catheter Precision's U.S. customer base for its VIVOTM system, a non-invasive arrhythmia location detection tool used prior to ventricular ablation procedures. The report also reiterates the status of the proposed stock-for-stock reverse merger between Ra Medical and Catheter Precision, originally announced on September 12, 2022.
Key Financial Metrics
This filing does not contain specific financial statements, revenue figures, profit margins, cash flow data, or debt levels for the current reporting period. It serves as a notification of a business event and a merger update. The document references previously filed financial data, including Catheter Precision's audited statements for the two-year period ended December 31, 2021, and unaudited statements for periods ended June 30, 2022, which were included in the Form 8-K filed on September 12, 2022.
Material Changes
- Customer Base Expansion: Catheter Precision has expanded its U.S. customer base for the VIVOTM system.
- Merger Status: The proposed merger remains pending, with an expected closing before the end of 2022, subject to shareholder approval and other closing conditions.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The combined company aims to focus on the cardiac electrophysiology market. Management notes that the merger is expected to close before the end of 2022. The filing includes forward-looking statements regarding the timing of the merger, future access to capital markets, and the commercialization of Catheter's products (VIVO, Amigo, and vessel closure devices).
Risks and Contingencies:
- Merger Conditions: Closing is contingent on shareholder approval, a minimum prevailing stock price for Ra Medical, and a specific Net Cash amount at closing. If the stock price drops below certain levels, the merger consideration for Catheter stockholders may be adversely impacted.
- Regulatory and Market Risks: Risks include potential delays, the application of "shell company" rules, and the ability to maintain a listing on the NYSE American.
- External Factors: The filing highlights risks related to the COVID-19 pandemic, economic uncertainty, and stock market volatility.
Investor Verification Checklist
- Verify the definitive proxy statement and Private Placement Memorandum (PPM) for detailed terms of the merger.
- Review the audited and unaudited financial statements of Catheter Precision filed in the September 12, 2022 Form 8-K (Exhibits 99.4, 99.5, and 99.6).
- Monitor Ra Medical's stock price to assess the risk of the minimum stock price condition for the merger closing.
- Confirm the status of shareholder approvals required for both Ra Medical and Catheter Precision.
- Examine the "Risk Factors" sections in the Preliminary Proxy Statement (Exhibits 99.7 and 99.8) for detailed merger and business risks.